Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Consolidated Net Income: 2014-2024

Historic Consolidated Net Income for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.0 million.

  • Viking Therapeutics' Consolidated Net Income fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • Latest data reveals that Viking Therapeutics reported Consolidated Net Income of -$110.0 million as of FY2024, which was down 28.17% from -$85.8 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Consolidated Net Income peaked at -$39.4 million during FY2020, and registered a low of -$110.0 million during FY2024.
  • For the 3-year period, Viking Therapeutics' Consolidated Net Income averaged around -$88.2 million, with its median value being -$85.8 million (2023).
  • Data for Viking Therapeutics' Consolidated Net Income shows a maximum YoY slumped of 53.80% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Viking Therapeutics' Consolidated Net Income stood at -$39.4 million in 2020, then crashed by 39.44% to -$55.0 million in 2021, then decreased by 25.08% to -$68.8 million in 2022, then fell by 24.78% to -$85.8 million in 2023, then fell by 28.17% to -$110.0 million in 2024.